Similarly, as observed in colorectal cancer, the POLR2A gene is almost always co-deleted with TP53 in the 17p deletion region in prostate cancer, and the expression levels of POLR2A, but not TP53, are significantly correlated with the loss of 17p (Supplementary Fig. 6a, b). Here, TP53 is linked to prostate carcinoma.